A phase-3 study of a once-daily, oral treatment for those living with focal seizures

• Randomized, Double-blind [study drug at 25mg, 15 mg or a placebo]
• Duration: 7 months
• Study visits: 9 study visits (7 Onsite and 2 telephone visits)
• Study activities:
  • Blood, Urine and Stool sample collection
  • Complete surveys/questionnaires
  • Eye Exam, ECG
• Compensation Provided

Inclusion criteria:

• Participant is 18 years or older.
• Participant is diagnosed with focal epilepsy for two years or more.
• Participant must have had a documented seizure frequency of ≥4 countable focal seizures per 28 days on average.
• Participant has tried 2 anti-seizure medications without lasting seizure freedom.
• Participant has been taking stable doses of 1 to 3 medications for seizures for at least 1 month.

Exclusion criteria:

• Participant has previously documented EEG which shows any pattern not consistent with focal etiology of seizures.
• Participant has a history of focal aware non-motor seizures only.
• Participant has a history of non-epileptic psychogenic seizures.
• Participant has a history of a primary generalized seizure.